SCHEMBL7149959

SCHEMBL7149959

Nc1nc(SCc2ccccc2)c([N+](=O)[O-])c(-c2ccco2)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 17/20 0.54
ADORA1 P30542 15/20 0.54
KDM4E B2RXH2 3/20 0.48
MEN1 O00255 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 3/20 0.48
KMT2A Q03164 3/20 0.48
USP2 O75604 2/20 0.48
ALOX15 P16050 2/20 0.48
HTT P42858 2/20 0.48
HSD17B10 Q99714 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
THRB P10828 1/20 0.48
NR4A1 P22736 1/20 0.48
MAPK1 P28482 1/20 0.48
PTPN7 P35236 1/20 0.48
RECQL P46063 1/20 0.48
DUSP3 P51452 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL7146724 0.82 ADORA2A (0.56) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7144408 0.81 ADORA2A (0.55) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL7149150 0.80 HPGD (0.53) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL5036755 0.80 ALDH1A1 (0.54) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL7149785 0.78 ADORA2A (0.66) ADORA2AADORA1MEN1ALDH1A1MAPT
SCHEMBL5039831 0.78 MGMT (0.65) ADORA2AADORA1
SCHEMBL5041333 0.77 MEN1 (0.69) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL4052390 0.77 ADORA2A (0.60) ADORA2AADORA1ADORA3ADORA2B
SCHEMBL7142633 0.76 ADORA2A (0.63) ADORA2AADORA1KDM4EMEN1ALDH1A1
SCHEMBL7141877 0.76 ADORA2A (0.53) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885KDM4E 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.